597 related articles for article (PubMed ID: 33097916)
1. Mutations and mechanisms of WNT pathway tumour suppressors in cancer.
Bugter JM; Fenderico N; Maurice MM
Nat Rev Cancer; 2021 Jan; 21(1):5-21. PubMed ID: 33097916
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
3. [Screening for Chemical Suppressors of the Wnt/β-catenin Signaling Pathway].
Nishiya N
Yakugaku Zasshi; 2017; 137(2):133-136. PubMed ID: 28154320
[TBL] [Abstract][Full Text] [Related]
4. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Wickström M; Dyberg C; Milosevic J; Einvik C; Calero R; Sveinbjörnsson B; Sandén E; Darabi A; Siesjö P; Kool M; Kogner P; Baryawno N; Johnsen JI
Nat Commun; 2015 Nov; 6():8904. PubMed ID: 26603103
[TBL] [Abstract][Full Text] [Related]
5. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
6. Wnt signaling in cancer.
Zhan T; Rindtorff N; Boutros M
Oncogene; 2017 Mar; 36(11):1461-1473. PubMed ID: 27617575
[TBL] [Abstract][Full Text] [Related]
7. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
8. Wnt Signaling and Drug Resistance in Cancer.
Zhong Z; Virshup DM
Mol Pharmacol; 2020 Feb; 97(2):72-89. PubMed ID: 31787618
[TBL] [Abstract][Full Text] [Related]
9. Wnt signaling as a therapeutic target for cancer.
Herbst A; Kolligs FT
Methods Mol Biol; 2007; 361():63-91. PubMed ID: 17172707
[TBL] [Abstract][Full Text] [Related]
10. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
11. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
[TBL] [Abstract][Full Text] [Related]
12. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities.
Nusse R; Clevers H
Cell; 2017 Jun; 169(6):985-999. PubMed ID: 28575679
[TBL] [Abstract][Full Text] [Related]
13. The Wnt pathway: emerging anticancer strategies.
Gupta A; Verma A; Mishra AK; Wadhwa G; Sharma SK; Jain CK
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):138-47. PubMed ID: 23432158
[TBL] [Abstract][Full Text] [Related]
14. Modulating β-catenin homeostasis for cancer therapy.
Xu Y; Yu Y; Yan R; Ke X; Qu Y
Trends Cancer; 2024 Jun; 10(6):507-518. PubMed ID: 38521655
[TBL] [Abstract][Full Text] [Related]
15. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Jiang X; Hao HX; Growney JD; Woolfenden S; Bottiglio C; Ng N; Lu B; Hsieh MH; Bagdasarian L; Meyer R; Smith TR; Avello M; Charlat O; Xie Y; Porter JA; Pan S; Liu J; McLaughlin ME; Cong F
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12649-54. PubMed ID: 23847203
[TBL] [Abstract][Full Text] [Related]
16. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
Dzobo K; Thomford NE; Senthebane DA
OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
[TBL] [Abstract][Full Text] [Related]
18. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
Song L; Li Y; He B; Gong Y
Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
[TBL] [Abstract][Full Text] [Related]
19. Can we safely target the WNT pathway?
Kahn M
Nat Rev Drug Discov; 2014 Jul; 13(7):513-32. PubMed ID: 24981364
[TBL] [Abstract][Full Text] [Related]
20. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
